Currently out of the existing stock ratings of Robbie Marcus, 190 are a BUY (61.09%), 102 are a HOLD (32.8%), 19 are a SELL (6.11%).
Analyst Robbie Marcus, currently employed at JPMORGAN, has had 62.41% of price targets met with an average potential upside of 19.05%, reached in 166 days on average.
Robbie Marcus has documented 609 price targets and ratings displayed on 38 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on NPCE, Neuropace.
Analyst best performing recommendations are on RXST (RXSIGHT).
The best stock recommendation documented was for INGN (INOGEN) on 5/8/2019. The price target of $72 was fulfilled within 1 day with a profit of $4.21 (6.21%), with a performance score of 62.1.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold
$0.74
$0.52 (236.36%)
$1
3 years 3 months 7 days ago
(08-Aug-2023)
5/8 (62.5%)
$0.1 (15.63%)
61
Hold
$1.5
$1.28 (581.82%)
4 years 2 months 30 days ago
(16-Aug-2022)
1/2 (50%)
$0.05 (3.45%)
2
Buy
$1.5
$1.28 (581.82%)
4 years 4 months 22 days ago
(24-Jun-2022)
1/5 (20%)
$0.96 (177.78%)
27
Sell
$19
5 years 3 days ago
(12-Nov-2021)
0/2 (0%)
$3.71 (16.84%)
Hold
$23
$21.36 (1302.44%)
$30
5 years 7 months 27 days ago
(19-Mar-2021)
0/3 (0%)
$4.37 (22.18%)
Which stock is Robbie Marcus most bullish on?
Which stock is Robbie Marcus most reserved on?
What Year was the first public recommendation made by Robbie Marcus?
